Predictors of Major Hemorrhage After Spleen Core Biopsy in Cancer Patients

J Vasc Interv Radiol. 2022 Sep;33(9):1055-1060.e1. doi: 10.1016/j.jvir.2022.06.002.

Abstract

In this retrospective study, 232 spleen biopsies from 218 patients with cancer were assessed. Biopsies resulting in hemorrhage requiring hospitalization, transfusion, or other interventions were compared with those that did not. The maximization of the Youden index helped determine the optimal systolic blood pressure (SBP) and platelet count thresholds. There were 15 (7%) major hemorrhages among 211 core biopsies. A multivariate logistic regression model showed that higher SBP, lower platelet count, and the lack of ultrasound guidance were independently associated with major hemorrhage (P < .05). The optimal SBP cutoff was 140 mm Hg, and the platelet count cutoff was 120,000 platelets/μL. In conclusion, the high major hemorrhage rate of 7% among percutaneous core spleen biopsies in patients with cancer may be mitigated by controlling SBP to <140 mm Hg and avoiding biopsy in patients with thrombocytopenia.

MeSH terms

  • Biopsy, Large-Core Needle / adverse effects
  • Hemorrhage / etiology
  • Humans
  • Neoplasms* / complications
  • Retrospective Studies
  • Spleen* / diagnostic imaging